Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ebiom.2020.102969 http://scihub22266oqcxt.onion/10.1016/j.ebiom.2020.102969 32853989!7445140!32853989     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EBioMedicine 2020 ; 59 (ä): 102969 Nephropedia Template TP {{tp|p=32853989|t=2020. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients |pdf=|usr=}}{{32853989}} gab.com Text Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients JO: EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32853989 #FOAvip Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases. Twit Text FOAVip Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients ????EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32853989 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32853989 #FOAvip English Wikipedia <ref>{{Cite pmid|32853989}}</ref> Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients #MMPMID32853989 Buijsers B; Yanginlar C; Maciej-Hulme ML; de Mast Q; van der Vlag J EBioMedicine 2020[Sep]; 59 (ä): 102969 PMID32853989show ga Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19. In part, this beneficial effect could be explained by the anticoagulant properties of heparin/LMWH. Here, we summarise potential beneficial, non-anticoagulant mechanisms underlying treatment of COVID-19 patients with heparin/LMWH, which include: (i) Inhibition of heparanase activity, responsible for endothelial leakage; (ii) Neutralisation of chemokines, and cytokines; (iii) Interference with leukocyte trafficking; (iv) Reducing viral cellular entry, and (v) Neutralisation of extracellular cytotoxic histones. Considering the multiple inflammatory and pathogenic mechanisms targeted by heparin/LMWH, it is warranted to conduct clinical studies that evaluate therapeutic doses of heparin/LMWH in COVID-19 patients. In addition, identification of specific heparin-derived sequences that are functional in targeting non-anticoagulant mechanisms may have even higher therapeutic potential for COVID-19 patients, and patients suffering from other inflammatory diseases. |Anti-Inflammatory Agents/metabolism/pharmacology/*therapeutic use[MESH] |Betacoronavirus/isolation & purification/physiology[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/pathology/virology[MESH] |Glucuronidase/antagonists & inhibitors/metabolism[MESH] |Heparin, Low-Molecular-Weight/metabolism/pharmacology/therapeutic use[MESH] |Heparin/metabolism/pharmacology/*therapeutic use[MESH] |Histones/blood/metabolism[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/pathology/virology[MESH] |SARS-CoV-2[MESH]Beneficial non-anticoagulant mechanisms underlying heparin treatment o(epmc).pdf DeepDyve Pubget Overpricing